SEC Form 4 · accession 0001140361-17-011329
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andreas Maetzel
Officer — Senior Vice President Medical
Period of report
Mar 8, 2017
Accepted (ET)
Mar 9, 2017 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $7.91 | Mar 8, 2017 | A | 65,000 | A | — | Mar 7, 2027 | Common Stock | 65,000 | 65,000 | D |
Explanation of responses
- F1The option vests over a 4 year period: 25% on March 8, 2018 after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.